Testing for HER2 in breast cancer.

摘要: HER2 is a paradigm of molecular target whose appropriate assessment pivotal in the targeting novel therapies for breast cancer, notably including Herceptin/Trastuzumab. Determining correct levels requires immunohistochemical and biological skills that are reproducible measurable, coupled with knowledge morphological pathobiological context. Attaining these goals not easy laboratories testing should maintain high level throughput tests engage recognized external quality assurance scheme. Fluorescence in-situ hybridization remains particular challenge there range strategies. This forms model identification other targets. In future rapid techniques such as real-time quantitative polymerase chain reaction (rqPCR), tissue microarrays or both bring significant economies cost scale.